The Society of Immunotherapy in Cancer (SITC), the European Society of Medical Oncology (ESMO), and the recent European Society of Cardiology (ESC) guidelines recommend obtaining baseline basic cardiac biomarkers such as troponin I, BNP, and ECG prior to the start of ICI therapy to establish an accurate reference for comparison, whereas the American Society of Clinical Oncology (ASCO) guidelines do not, stating that “there is no clear evidence regarding the efficacy or value of routine ECGs or troponin measurements in patients receiving checkpoint inhibitor therapy” [27,28,29]. The gene discussed is NPPB; the disease is cancer.